by Stacey Johnson | Sep 18, 2026
I went down a bit of a rabbit hole the other day, as one often does on the internet and/or social media. In my defence, I was looking for inspiration for my next blog post – this one – and I found some. It started with this parody song about placebos, by anesthetist...
by Stacey Johnson | Jul 23, 2026
“Regulatory approval does not translate to dollars for a company, nor does it lead to patients being treated. Without reimbursement, all of the efforts of translation and development are lost.” My former colleague, Mark Curtis, wrote these words back when he blogged...
by Stacey Johnson | Jul 9, 2026
Celebrity health stories often dominate headlines, but their impact extends beyond entertainment news. High-profile diagnoses can raise awareness of rare diseases, increase participation in clinical trials, influence health policy, and accelerate investment in...
by Michael May | Jun 9, 2026
Fifteen years ago, regenerative medicine in Canada stood at an inflection point. The science was world-class, the academic talent was undeniable, and the promise of cell and gene therapies was beginning to capture global attention. Yet there was a critical problem:...
by Sanat Khanna | May 12, 2026
Cell therapy manufacturing generates large volumes of process data – from sensors, bioreactors, quality controls and genomic assays. In many facilities, much of that data are collected for regulatory compliance rather than for process improvement – a pattern that...
by Lyla El-Fayomi | Mar 12, 2026
Somehow we are already into March, and spring – at least in some places – feels close by. To catch you up, I’ve put together a recap of some of the research that scientists were buzzing about in the field of regenerative medicine from 2025; I cover the good, the bad,...
Comments